EVAXEvaxion Biotech A/S

Nasdaq evaxion-biotech.com


$ 3.22 $ -0.06 (-1.88 %)    

Wednesday, 11-Sep-2024 15:53:04 EDT
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 3.14
$ 3.27
$ 3.10 x 100
-- x --
$ 3.14 - $ 3.27
$ 2.26 - $ 13.61
24,238
na
119M
$ 1.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evaxion-biotech-unveils-pre-clinical-results-for-mrna-based-gonorrhea-vaccine

Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunolog...

 hc-wainwright--co-reiterates-buy-on-evaxion-biotech-maintains-14-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14...

 evaxion-to-present-1-year-clinical-efficacy-data-from-its-phase-2-study-on-lead-cancer-vaccine-candidate-evx-01-at-the-esmo-congress-2024

Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunolog...

 hc-wainwright--co-reiterates-buy-on-evaxion-biotech-maintains-14-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14...

 evaxion-ceo-christian-kanstrup-reinforces-milestone-timeline-and-provides-shareholder-update

Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing i...

 hc-wainwright--co-reiterates-buy-on-evaxion-biotech-maintains-14-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14...

 evaxion-presents-validating-immune-data-from-ongoing-phase-2-trial-with-ai-designed-evx-01-vaccine-at-the-asco-annual-meeting-2024

Evaxion's AI-designed cancer vaccine, EVX-01, triggered a specific and tumor-targeting immune response in all assayed melan...

 evaxion-biotech-q1-eps-003-beats-056-estimate-sales-5100k-beat-3700k-estimate

Evaxion Biotech (NASDAQ:EVAX) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.5...

 evaxion-received-a-letter-from-the-nasdaq-listing-qualifications-department-notifying-that-it-is-not-currently-in-compliance-with-the-minimum-stockholders-equity-requirement

Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing i...

 hc-wainwright--co-reiterates-buy-on-evaxion-biotech-maintains-14-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION